H.C. Wainwright, a US-based investment bank, has revised its price target for OnKure Therapeutics (NASDAQ: OKUR) to $21 per share, citing valuation adjustments in a research note published this week. The cut represents a recalibration of the firm's model for the clinical-stage biopharmaceutical company, which focuses on precision oncology treatments.
OnKure shares were trading around $15.50 on Monday, down roughly 3% on the day, as investors digested the analyst downgrade. The broader Nasdaq Biotechnology Index edged 0.2% lower, reflecting a cautious tone across the sector. The FTSE 100 closed flat at 8,212 points on Tuesday, with UK-listed biotech names such as AstraZeneca and GSK showing limited reaction to the US-focused news.
Analysts at H.C. Wainwright maintained their 'Buy' rating on the stock, suggesting the price target reduction does not signal a loss of confidence in OnKure's pipeline. Instead, the move appears to reflect updated assumptions around discount rates and market comparables. OnKure's lead candidate, a targeted therapy for certain solid tumours, remains in early-stage clinical trials.
For UK investors, the impact is indirect but notable. OnKure is not listed on the London Stock Exchange, meaning UK pension funds and retail investors with diversified global portfolios may have minimal direct exposure. However, the broader biotech sector remains a key area for UK life sciences investment, with companies like Oxford Nanopore and Immunocore tracking similar sentiment trends.
Market observers note that price target adjustments by US analysts often influence sentiment across Atlantic-listed healthcare stocks. The FTSE All-Share index was little changed on the day, while the pound traded at $1.29 against the dollar. No further guidance from OnKure management has been issued in response to the note.